In the original article, there was a mistake in Figure 3 as published. While preparing the figures, the labels of the bar charts in Figure 3 were misspelled. The corrected Figure 3 appears below.
Figure 3
In the published article, there was also an error in affiliation 3. Instead of “Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China”, it should be “Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China”.
There was a further error as an affiliation was omitted for authors Minjia Wang, Chengzhi Huang and Xueqing Yao. These authors should also have affiliation 5 – “School of Medicine, South China University of Technology, Guangzhou, China”.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
oxaliplatin, chemoresistance, siRNA delivery, colorectal cancer, ATP7A
Citation
Zhou Y, Zhang Q, Wang M, Huang C and Yao X (2022) Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer. Front. Oncol. 12:916983. doi: 10.3389/fonc.2022.916983
Received
10 April 2022
Accepted
09 May 2022
Published
27 June 2022
Volume
12 - 2022
Edited and reviewed by
Zeming Liu, Huazhong University of Science and Technology, China
Updates
Copyright
© 2022 Zhou, Zhang, Wang, Huang and Yao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xueqing Yao, syyaoxueqing@scut.edu.cn; Chengzhi Huang, huangchengzhi93@hotmail.com
†These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.